6 results about "Acute alcoholism" patented technology

The application discloses a high-activity UGT1A1 enzyme based on tree shrew and a feed composition for enhancing alcohol metabolism. The catalytic efficiency of the recombinant tree shrew UGT1A1 enzyme on ethanol is significantly higher than that of human isozyme. The core of the application is to provide a complex feed system containing the enzyme, which solves the key bottleneck of poor stability and low delivery efficiency of exogenous enzymes in application through the synergistic effect of enzyme stabilizers, cell penetration enhancers, enteric coatings and coenzyme supply agents. Animal experiments show that the composition can safely and effectively accelerate in vivo alcohol elimination and reduce blood ethanol concentration, and can be used for developing alcoholism products, acute alcoholism treatment drugs and alcoholic liver disease prevention preparations.

The invention relates to the technical field of microorganisms, and discloses a plant lactobacillus XJSN202504 and application thereof in acute alcoholism, the plant lactobacillus XJSN202504 is preserved in China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.34746, and the preservation time is June 3, 2025. The invention further discloses a preparation method of the plant lactobacillus XJSN202504. The lactobacillus plantarum XJSN202504 disclosed by the invention can be used for improving liver injury related indexes in serum and expression of inflammation related genes, and also can be used for adjusting the activity of antioxidant enzymes in the liver and relieving alcohol-induced oxidative stress injury; moreover, gastric mucosa, small intestine and colon injuries caused by a large amount of alcohol can be effectively prevented, the anti-inflammatory activity and the antioxidant activity are better, the anti-alcohol function can be achieved through gastrointestinal tracts, and the effects of protecting liver and digestive tract mucosa are achieved.

The application belongs to the field of pharmacy, discloses a fused ring morphine derivative and a preparation method and application thereof, and relates to N-cyclopropylmethyl-4'-substituted aminonalepotem series derivatives with formula (I) and pharmaceutically acceptable salts. The derivative with formula (I) is prepared by reacting thebaine with a substituted phenyl vinyl ketone reagent and through a series of conversion methods. Among them, N-cyclopropylmethyl-(4'-benzoyl amino) nalepotem (SLL-1062) is a typical high selectivity mu opioid receptor antagonist, and can be applied to the research and development in the fields of diagnosis and treatment of opioid and other narcotic analgesic dependence, opioid drug-induced intestinal dysfunction, sedative hypnotics and acute alcohol poisoning, opioid and other narcotic analgesic poisoning and the like.

This invention discloses an orally disintegrating film formulation of BPC-157 sodium salt for treating acute alcohol poisoning and its preparation method. It relates to the field of acute alcohol poisoning treatment technology. The orally disintegrating film formulation comprises, by weight percentage: 0.1-5% BPC-157 sodium salt, 40-70% film-forming material, 5-15% plasticizer, 0.1-15% disintegrant, 0.1-15% sweetener, 0.1-10% salivary stimulant, and 1-5% other excipients. This invention prepares an orally disintegrating film formulation of BPC-157 sodium salt, utilizing its rapid dissolution characteristics and the pharmacological effects of BPC-157, providing a new option for treating acute alcohol poisoning. This formulation has advantages such as rapid onset of action, high bioavailability, and few side effects, and is expected to become an effective drug for treating acute alcohol poisoning.

The invention discloses a chalcone-lignan glycoside compound separated from hovenia dulcis thunb and an application of the chalcone-lignan glycoside compound in dispelling effects of alcohol and protecting liver. The structure of the aurone-lignan glycoside compound is shown as a formula I or pharmaceutically acceptable salt of the aurone-lignan glycoside compound. The chalcone-lignan glycoside compound can obviously shorten the sobering time of mice suffering from acute alcoholism, reduce the number of autonomous activities of the mice, reduce the content of MDA in the livers of the mice and improve the activity of ADH, SOD and GSH-Px in the livers of the mice, and has remarkable effects of dispelling the effects of alcohol and protecting the liver. The invention discloses application of the chalcone-lignan glycoside compound in preparation of a medicine for dispelling the effects of alcohol and protecting the liver. The invention discloses an application of the chalcone-lignan glycoside compound in preparation of a medicine for treating acute and chronic alcoholic liver injury, and further discloses an application of the chalcone-lignan glycoside compound in preparation of a medicine for treating acute and chronic alcoholic liver injury.

This invention provides a compound, its preparation method, a pharmaceutical composition, and its applications, relating to the field of pharmaceutical technology. The compound provided by this invention has the structure shown in Formula I. This compound can effectively relieve acute alcohol poisoning and protect the liver from damage. In vitro cell experiments show that this compound can accelerate the excretion of ethanol, acetaldehyde, and their metabolites in vivo, protect hepatocytes from acetaldehyde-induced lipid peroxidation, and prevent acetaldehyde-induced glutathione reduction. In a mouse model of acute alcohol poisoning, this compound can significantly delay the onset of intoxication and significantly accelerate the sobering-up time. Furthermore, the compound provided by this invention has low toxicity and good drug-like properties. This invention provides a method for preparing the compound with the structure shown in Formula I, which is simple to synthesize and has a high yield.